GB750373A
(en)
|
1953-01-15 |
1956-06-13 |
Pfizer & Co C |
Improvements in or relating to injectable suspension of penicillin salts
|
DK128416B
(en)
|
1964-08-13 |
1974-04-29 |
Ciba Geigy Ag |
Analogous process for the preparation of adrenocorticotropically active nonadecapeptide amides or acid addition salts or complex compounds thereof.
|
BE757195A
(en)
|
1969-10-07 |
1971-03-16 |
Century Disposable Devices |
SYRINGE FOR INJECTING A FRESHLY PREPARED MIXTURE OF POWDER AND LIQUID
|
JPS5270014A
(en)
|
1975-12-05 |
1977-06-10 |
Senju Pharma Co |
Stabilization of pyrido*3*22a*phenoxadine compounds
|
US4171698A
(en)
|
1977-08-15 |
1979-10-23 |
Abbott Laboratories |
Prefilled two-compartment syringe
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
ATE81872T1
(en)
|
1985-03-15 |
1992-11-15 |
James Summerton |
STEROREOGULAR POLYNUCLEOTIDE BINDING POLYMERS.
|
AU4128089A
(en)
|
1988-09-15 |
1990-03-22 |
Rorer International (Overseas) Inc. |
Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
|
US5001000A
(en)
|
1988-09-26 |
1991-03-19 |
E. I. Du Pont De Nemours And Company |
Process for forming a composite structure of thermoplastic polymer and sheet molding compound
|
US5114703A
(en)
*
|
1989-05-30 |
1992-05-19 |
Alliance Pharmaceutical Corp. |
Percutaneous lymphography using particulate fluorocarbon emulsions
|
US5730978A
(en)
|
1989-09-01 |
1998-03-24 |
Fred Hutchinson Cancer Research Center |
Inhibition of lymphocyte adherence with α4β1-specific antibodies
|
US6033665A
(en)
|
1989-09-27 |
2000-03-07 |
Elan Pharmaceuticals, Inc. |
Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
|
JPH03190823A
(en)
|
1989-12-21 |
1991-08-20 |
Snow Brand Milk Prod Co Ltd |
Erythropoietin hypodermic or intramuscular administration agent
|
US5698195A
(en)
|
1991-03-18 |
1997-12-16 |
New York University Medical Center |
Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
LU91067I2
(en)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab and its variants and immunochemical derivatives including immotoxins
|
US5356802A
(en)
|
1992-04-03 |
1994-10-18 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease
|
US5487994A
(en)
|
1992-04-03 |
1996-01-30 |
The Johns Hopkins University |
Insertion and deletion mutants of FokI restriction endonuclease
|
US5436150A
(en)
|
1992-04-03 |
1995-07-25 |
The Johns Hopkins University |
Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
ATE182625T1
(en)
|
1993-01-12 |
1999-08-15 |
Biogen Inc |
RECOMBINANT ANTI-VLA4 ANTIBODIES MOLECULES
|
US5334162A
(en)
|
1993-03-15 |
1994-08-02 |
Eli Lilly And Company |
Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
|
US5744155A
(en)
*
|
1993-08-13 |
1998-04-28 |
Friedman; Doron |
Bioadhesive emulsion preparations for enhanced drug delivery
|
US5527675A
(en)
|
1993-08-20 |
1996-06-18 |
Millipore Corporation |
Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
|
DE4331012A1
(en)
|
1993-09-13 |
1995-03-16 |
Bayer Ag |
Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
|
DE4344824C1
(en)
|
1993-12-28 |
1995-08-31 |
Immuno Ag |
Highly concentrated immunoglobulin preparation and process for its preparation
|
US5840299A
(en)
|
1994-01-25 |
1998-11-24 |
Athena Neurosciences, Inc. |
Humanized antibodies against leukocyte adhesion molecule VLA-4
|
GB9418092D0
(en)
|
1994-09-08 |
1994-10-26 |
Red Cross Found Cent Lab Blood |
Organic compounds
|
JP3524974B2
(en)
|
1994-12-26 |
2004-05-10 |
ブラッコ インターナショナル ビーヴィ |
Prefilled syringe and package thereof
|
US5569193A
(en)
|
1995-03-22 |
1996-10-29 |
Abbott Laboratories |
Syringe system accommodating separately storable prefilled containers for two constituents
|
US5779668A
(en)
|
1995-03-29 |
1998-07-14 |
Abbott Laboratories |
Syringe barrel for lyophilization, reconstitution and administration
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
US6685940B2
(en)
|
1995-07-27 |
2004-02-03 |
Genentech, Inc. |
Protein formulation
|
DE19617369A1
(en)
|
1996-04-30 |
1997-11-06 |
Immuno Ag |
Storage-stable fibrinogen preparations
|
US6184037B1
(en)
*
|
1996-05-17 |
2001-02-06 |
Genemedicine, Inc. |
Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
US5819998A
(en)
|
1996-09-30 |
1998-10-13 |
Everything Kids |
Knapsack with simulated basketball court
|
IN184589B
(en)
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US5819988A
(en)
|
1997-04-01 |
1998-10-13 |
Sawhney; Ravi K. |
Double-barreled syringe with detachable locking mixing tip
|
US6065645A
(en)
|
1997-04-01 |
2000-05-23 |
Discus Dental Impressions, Inc. |
Double-barreled syringe with detachable locking mixing tip
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US5786571A
(en)
|
1997-05-09 |
1998-07-28 |
Lexmark International, Inc. |
Wrapped temperature sensing assembly
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
ATE358496T1
(en)
|
1997-10-15 |
2007-04-15 |
Asahi Kasei Pharma Corp |
METHOD FOR QUALITY ASSURANCE OF AQUEOUS PARENTERAL SOLUTIONS WITH THROMBOMODULIN IN STORAGE AND DISTRIBUTION
|
JP3480941B2
(en)
|
1997-10-22 |
2003-12-22 |
中外製薬株式会社 |
Screening method for TGF-β inhibitor
|
US7919109B2
(en)
|
1999-02-08 |
2011-04-05 |
Intarcia Therapeutics, Inc. |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
|
FR2794649B1
(en)
*
|
1999-06-11 |
2003-04-11 |
Solutions |
BIOMATERIAL BASED ON AN INSOLUBILIZED DEXTRAN DERIVATIVE AND A GROWTH FACTOR, METHOD FOR PREPARING SAME AND ITS APPLICATIONS
|
AUPQ132599A0
(en)
*
|
1999-07-01 |
1999-07-22 |
Commonwealth Scientific And Industrial Research Organisation |
Nasogastric enteral formulations
|
US7030097B1
(en)
|
1999-07-14 |
2006-04-18 |
Cornell Research Foundation, Inc. |
Controlled nucleic acid delivery systems
|
EP1072323B1
(en)
|
1999-07-29 |
2003-09-10 |
Wilhelm A. Keller |
Cartridge discharge device with actuator for dynamic mixers
|
ATE345810T1
(en)
|
1999-10-04 |
2006-12-15 |
Novartis Vaccines & Diagnostic |
STABILIZED LIQUID PHARMACEUTICAL COMPOSITION CONTAINING POLYPEPTIDES
|
US6394314B1
(en)
|
1999-10-12 |
2002-05-28 |
Discus Dental Impressions, Inc. |
Double-barreled syringe with detachable locking mixing tip
|
US6443612B1
(en)
|
1999-12-02 |
2002-09-03 |
Wilhelm A. Keller |
Dynamic mixer
|
EP1324776B2
(en)
|
2000-10-12 |
2018-03-21 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US7931614B2
(en)
|
2000-11-30 |
2011-04-26 |
Valeritas, Inc. |
Injection systems
|
DK2813582T3
(en)
|
2000-12-01 |
2017-07-31 |
Max-Planck-Gesellschaft Zur Förderung Der Wss E V |
Small RNA molecules that mediate RNA interference
|
CA2446127A1
(en)
|
2001-05-16 |
2002-11-21 |
Biomarin Pharmaceutical Inc. |
Destruction of prions using vibriolysin or variants thereof
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
WO2003009817A2
(en)
|
2001-07-25 |
2003-02-06 |
Protein Design Labs, Inc. |
Stable lyophilized pharmaceutical formulation of igg antibodies
|
US7101819B2
(en)
|
2001-08-02 |
2006-09-05 |
3M Innovative Properties Company |
Alumina-zirconia, and methods of making and using the same
|
JP4167820B2
(en)
|
2001-10-19 |
2008-10-22 |
アルインコ株式会社 |
Deck plate traveling cart
|
GB0212405D0
(en)
|
2002-05-29 |
2002-07-10 |
Insignion Holdings Ltd |
Composition and its therapeutic use
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
WO2004055164A2
(en)
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
DK2163643T3
(en)
|
2003-03-05 |
2015-03-23 |
Halozyme Inc |
Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered
|
AR043811A1
(en)
|
2003-03-31 |
2005-08-17 |
Alza Corp |
NON-WATERPROOF SINGLE PHASE VEHICLES AND FORMULATIONS USING THESE VEHICLES
|
LT2335725T
(en)
|
2003-04-04 |
2017-01-25 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
US20050158303A1
(en)
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
US7341843B2
(en)
|
2003-04-11 |
2008-03-11 |
Allergan, Inc. |
Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
|
EP1616004A1
(en)
|
2003-04-15 |
2006-01-18 |
Ista Pharmaceuticals, Inc |
Process for isolating and purifing ovine hyaluronidase
|
WO2004103342A2
(en)
*
|
2003-05-16 |
2004-12-02 |
Alkermes Controlled Therapeutics, Inc. |
Injectable sustained release compositions
|
US20070184084A1
(en)
*
|
2003-05-30 |
2007-08-09 |
Guohua Chen |
Implantable elastomeric caprolactone depot compositions and uses thereof
|
MXPA05014171A
(en)
*
|
2003-06-23 |
2007-02-21 |
Sanofi Pasteur Inc |
Immunization method against neisseria meningitidis.
|
CN1206344C
(en)
*
|
2003-07-28 |
2005-06-15 |
中国海洋大学 |
Method for producing fucan sulfatase by means of bacteria
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
JP2007523050A
(en)
|
2003-09-17 |
2007-08-16 |
カイアズマ・リミテッド |
Composition that can facilitate permeation through biological barriers
|
EP1532983A1
(en)
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
GB0403938D0
(en)
|
2004-02-21 |
2004-03-24 |
West Pharm Serv Drug Res Ltd |
Chitosan containing solution
|
ATE469191T1
(en)
|
2004-11-25 |
2010-06-15 |
Chr Hansen As |
METHOD FOR PRODUCING A CARMINAL ACID LACQUER
|
US20060141040A1
(en)
|
2004-12-23 |
2006-06-29 |
Guohua Chen |
Injectable non-aqueous suspension
|
US20060142234A1
(en)
|
2004-12-23 |
2006-06-29 |
Guohua Chen |
Injectable non-aqueous suspension
|
CA2625004C
(en)
|
2005-10-07 |
2015-10-06 |
The University Of Alabama |
Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
|
CN100416002C
(en)
|
2005-10-26 |
2008-09-03 |
曲新华 |
Sewage recycling apparatus
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
TW201008595A
(en)
|
2005-12-20 |
2010-03-01 |
Bristol Myers Squibb Co |
Stable protein formulations
|
BRPI0620316A2
(en)
|
2005-12-21 |
2011-11-08 |
Wyeth Corp |
Low viscosity protein formulations and their uses
|
EP1977763A4
(en)
|
2005-12-28 |
2010-06-02 |
Chugai Pharmaceutical Co Ltd |
Antibody-containing stabilizing preparation
|
JP2009525986A
(en)
|
2006-02-03 |
2009-07-16 |
メディミューン,エルエルシー |
Protein preparation
|
DE102006005094A1
(en)
|
2006-02-04 |
2007-08-09 |
Degussa Gmbh |
Titanium dioxide and polycarboxylate ether-containing dispersion
|
ITMI20061030A1
(en)
*
|
2006-05-26 |
2007-11-27 |
Altergon Sa |
NEW COMPOSITION INCLUDING GLYCOSAMINOGLICANS WITH CONTROLLED VISCOSITY AND USE OF SUCH COMPOSITION IN THE THERAPY OF CHRONIC CYSTITIS
|
CU23526B6
(en)
|
2006-10-03 |
2010-05-19 |
Ct Ingenieria Genetica Biotech |
METHOD FOR MORFOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY
|
WO2008092084A2
(en)
|
2007-01-26 |
2008-07-31 |
Centocor, Inc. |
Injectable non-aqueous suspension with high concentration of therapeutic agent
|
EP2162117B1
(en)
|
2007-05-31 |
2018-02-21 |
Anterios, Inc. |
Nucleic acid nanoparticles and uses therefor
|
WO2009015367A2
(en)
|
2007-07-25 |
2009-01-29 |
Arizona Board Of Regents For And On Behalf Of Arizona State University |
Stabilizing proteins using ionic liquids
|
WO2009026122A1
(en)
|
2007-08-17 |
2009-02-26 |
Amgen Inc. |
Formulations of antibodies and fc-fusion molecules using polycations
|
US8383114B2
(en)
*
|
2007-09-27 |
2013-02-26 |
Amgen Inc. |
Pharmaceutical formulations
|
US8552046B2
(en)
*
|
2007-10-16 |
2013-10-08 |
Pharmacyclics, Inc. |
Manufacture, compositions and uses of coagulation factor VIIa modulator
|
EP3381445B1
(en)
|
2007-11-15 |
2023-10-25 |
Amgen Inc. |
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
|
WO2009086062A1
(en)
|
2007-12-21 |
2009-07-09 |
Lyotropic Therapeutics, Inc. |
Stabilized formulations of peptides and proteins
|
PE20091174A1
(en)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
US20110065675A1
(en)
|
2008-05-05 |
2011-03-17 |
University Of Miami |
Azo dye related small molecule modulators of protein-protein interactions
|
EP2123307A1
(en)
|
2008-05-20 |
2009-11-25 |
Hexal Ag |
Method for reducing leachables and extractables in syringes
|
KR20110103961A
(en)
|
2008-11-16 |
2011-09-21 |
보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 |
Low viscosity highly concentrated suspensions
|
TWI342781B
(en)
|
2008-12-01 |
2011-06-01 |
Univ China Medical |
Blood sugar-modulating polypeptides
|
CN102414221A
(en)
|
2009-03-06 |
2012-04-11 |
健泰科生物技术公司 |
Antibody formulation
|
WO2010132047A1
(en)
|
2009-05-14 |
2010-11-18 |
Rensselaer Polytechnic Institute |
Guanosine/gmp gels and uses thereof
|
KR20120024610A
(en)
|
2009-05-20 |
2012-03-14 |
세키스이 메디칼 가부시키가이샤 |
Blood coagulation time prolonging agent
|
WO2010148253A2
(en)
|
2009-06-17 |
2010-12-23 |
Zystor Therapeutics, Inc. |
Formulations for lysosomal enzymes
|
WO2011017330A1
(en)
|
2009-08-04 |
2011-02-10 |
Genentech Inc |
Concentrated polypeptide formulations with reduced viscosity
|
WO2011034604A2
(en)
|
2009-09-17 |
2011-03-24 |
Baxter Healthcare, S.A. |
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
|
WO2011050000A2
(en)
|
2009-10-20 |
2011-04-28 |
The Regents Of The University Of California |
Single molecule nucleic acid nanoparticles
|
UY32979A
(en)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
|
PT3721904T
(en)
|
2009-11-20 |
2021-11-15 |
Biocon Ltd |
Formulations of t1h antibody
|
US9289381B2
(en)
|
2009-12-03 |
2016-03-22 |
The University Of North Carolina At Charlotte |
Stabilization and storage of biological pharmaceutical compositions
|
SG181601A1
(en)
|
2009-12-10 |
2012-07-30 |
Univ Minnesota |
Tal effector-mediated dna modification
|
US8715651B2
(en)
|
2010-01-08 |
2014-05-06 |
Chanel Parfums Beaute |
Use of at least one extract of flowers of Camellia japonica alba plena for moisturizing the skin
|
JP6078344B2
(en)
|
2010-02-04 |
2017-02-08 |
ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト |
Immunoglobulin preparation
|
EP3216462A3
(en)
*
|
2010-02-26 |
2017-12-20 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
NZ602685A
(en)
|
2010-03-01 |
2014-10-31 |
Cytodyn Inc |
Concentrated protein formulations and uses thereof
|
US20130171128A1
(en)
|
2010-03-02 |
2013-07-04 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
BR112012023895A2
(en)
|
2010-03-17 |
2016-11-29 |
Abbott Res Bv |
anti nerve growth factor (ngf) compositions
|
WO2011121560A2
(en)
|
2010-03-31 |
2011-10-06 |
Universite De Geneve |
Stabilized antibody preparations and uses thereof
|
CN101851267A
(en)
|
2010-04-22 |
2010-10-06 |
江南大学 |
Antibody protective agent and application thereof
|
JP2013525484A
(en)
|
2010-05-03 |
2013-06-20 |
ジェネンテック, インコーポレイテッド |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
GB201012179D0
(en)
|
2010-07-20 |
2010-09-01 |
Future Injection Technologies |
Injection device
|
US8936827B2
(en)
*
|
2011-02-25 |
2015-01-20 |
Abbott Cardiovascular Systems Inc. |
Methods of loading a hollow stent with a drug or drug formulation
|
AU2012240050B2
(en)
|
2011-04-07 |
2016-01-21 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
US20140044727A1
(en)
|
2011-04-07 |
2014-02-13 |
Glaxosmithkline Llc |
Formulations with reduced viscosity
|
CN103619368B
(en)
*
|
2011-05-12 |
2017-02-08 |
拜耳医药保健有限公司 |
Fluid injection system having various systems for controlling an injection procedure
|
RU2485133C2
(en)
|
2011-05-30 |
2013-06-20 |
Закрытое Акционерное Общество "Фарм-Синтез" |
Protein-polypeptide complex possessing tissue-specific regenerative-reparative and rejuvenating action on skin tissue, method for preparing it, and pharmaceutical composition thereof
|
US9241869B2
(en)
|
2011-10-25 |
2016-01-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
MX352823B
(en)
|
2011-10-28 |
2017-12-04 |
Integritybio Inc |
Protein formulations containing amino acids.
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
CA2899433A1
(en)
|
2012-01-27 |
2013-08-01 |
Gliknik Inc. |
Fusion proteins comprising igg2 hinge domains
|
MX370199B
(en)
|
2012-02-16 |
2019-12-05 |
Santarus Inc |
Anti-vla1 (cd49a) antibody pharmaceutical compositions.
|
US9574193B2
(en)
*
|
2012-05-17 |
2017-02-21 |
Ionis Pharmaceuticals, Inc. |
Methods and compositions for modulating apolipoprotein (a) expression
|
US20160002624A1
(en)
*
|
2012-05-17 |
2016-01-07 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide compositions
|
EP3427721A1
(en)
|
2012-05-18 |
2019-01-16 |
Genentech, Inc. |
High-concentration monoclonal antibody formulations
|
PL2800811T3
(en)
|
2012-05-25 |
2017-11-30 |
Emmanuelle Charpentier |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
AU2013265255B2
(en)
*
|
2012-05-25 |
2018-03-29 |
Novartis Ag |
Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
|
MA37777B1
(en)
|
2012-06-21 |
2017-07-31 |
Ucb Pharma Sa |
Pharmaceutical preparation
|
CN116622704A
(en)
|
2012-07-25 |
2023-08-22 |
布罗德研究所有限公司 |
Inducible DNA binding proteins and genomic disruption tools and uses thereof
|
CN109705218B
(en)
|
2012-08-09 |
2022-07-19 |
罗切格利卡特公司 |
ASGPR antibodies and uses thereof
|
FR2994390B1
(en)
|
2012-08-10 |
2014-08-15 |
Adocia |
METHOD FOR LOWERING THE VISCOSITY OF HIGH CONCENTRATION PROTEIN SOLUTIONS
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
FR2995214B1
(en)
|
2012-09-10 |
2014-11-21 |
Adocia |
REDUCED VISCOSITY SOLUTION OF HIGH CONCENTRATION PROTEIN
|
EP2968873A4
(en)
*
|
2013-03-13 |
2016-10-26 |
Applied Cardiovascular Solutions Llc |
Methods, compositions, and devices for the occlusion of cavities and passageways
|
US9669242B2
(en)
|
2013-07-01 |
2017-06-06 |
L'oreal |
Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
|
KR102651018B1
(en)
|
2013-09-11 |
2024-03-27 |
이글 바이오로직스 인코퍼레이티드 |
Liquid protein formulations containing viscosity-lowering agents
|
WO2015196091A1
(en)
|
2014-06-20 |
2015-12-23 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|